Intercure files Form D covering equity issued for Botanico acquisition

Intercure Ltd., an Israel-based pharmaceuticals company headquartered in Hertzliya, filed a Form D with the SEC disclosing a new notice of exempt securities offering. The filing lists the type of filing as a new notice, with a date of first sale of June 15, 2026.¹

The offering is tied to a corporate transaction. The company confirmed the offering is being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer.¹ In its own clarifying language, the filing describes the transaction as the first closing of an acquisition of ISHI (Botanico Ltd.) by Intercure Ltd. in consideration of InterCure's Ltd.'s ordinary shares and options to purchase ordinary shares.¹

The securities offered include equity and an option, warrant, or other right to acquire another security¹. The filing claims exemption under Rule 506(b)¹ of Regulation D.

According to the filing, the total amount sold was $0 USD, and the total offering amount and total remaining to be sold were both listed as indefinite¹. Sales commissions and finders' fees were both reported as $0 USD¹, and the minimum investment accepted from any outside investor was listed as $0 USD¹.

The filing indicates that a total of 15 investors have already invested in the offering.¹

The Form D was signed by Amos Cohen, Chief Financial Officer of Intercure Ltd., on August 19, 2026¹. Related persons named in the filing include Alexander Rabinovich, identified as Chief Executive Officer and Chairman of the Board of Directors¹, along with directors David Salton, Lennie Michelson Grinbaum, and Gideon Hirschfeld.